Cargando…
FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab
BACKGROUND: Immunotherapy has demonstrated remarkable success in treating different cancers. Nonetheless, a large number of patients do not respond, many respond without immediate changes detectable with conventional imaging, and many have unusual immune-related adverse events that cannot be predict...
Autores principales: | Scarpelli, Matthew, Zahm, Christopher, Perlman, Scott, McNeel, Douglas G., Jeraj, Robert, Liu, Glenn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354338/ https://www.ncbi.nlm.nih.gov/pubmed/30700328 http://dx.doi.org/10.1186/s40425-019-0516-1 |
Ejemplares similares
-
Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer
por: McNeel, Douglas G., et al.
Publicado: (2018) -
Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
por: McNeel, Douglas G, et al.
Publicado: (2022) -
FLT PET-CT in evaluation of treatment response
por: Sanghera, Bal, et al.
Publicado: (2014) -
Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
por: Gamat-Huber, Melissa, et al.
Publicado: (2020) -
(18)F-FLT PET/CT in Patients with Gastric Carcinoma
por: Małkowski, Bogdan, et al.
Publicado: (2013)